15257-93-9Relevant articles and documents
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment
He, Kaiyong,Jiang, Min,Liu, Qi,Qiu, Tong,Sun, Jiahui,Zhang, Xueqiong,Zheng, Hua
, (2020)
We induced changes in the tumor microenvironment (TME) through the synergistic actions of two drugs used in breast cancer therapy. The anti-fibrotic drug silibinin (SLB) targets tumor-associated fibroblasts and exerts immune-mediated anti-cancer effects.